Epacadostat
- Generic Name
- Epacadostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C11H13BrFN7O4S
- CAS Number
- 1204669-58-8
- Unique Ingredient Identifier
- 71596A9R13
- Background
Epacadostat has been used in trials studying the treatment of HL, Melanoma, Glioblastoma, Mucosal Melanoma, and Ovarian Carcinoma, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 45
- Registration Number
- NCT02364076
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
- First Posted Date
- 2014-12-30
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 307
- Registration Number
- NCT02327078
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT02298153
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
- First Posted Date
- 2014-06-18
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02166905
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Conditions
- Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7Stage III Fallopian Tube Cancer AJCC v7Stage IIIA Primary Peritoneal Cancer AJCC v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIB Ovarian Cancer AJCC v6 and v7Stage IIIA Ovarian Cancer AJCC v6 and v7
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT02042430
- Locations
- 🇺🇸
University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-10-11
- Last Posted Date
- 2018-06-08
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01961115
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2012-09-14
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 83
- Registration Number
- NCT01685255
A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
- First Posted Date
- 2012-05-24
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT01604889
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.